Oxford BioTherapeutics
Precision cancer immunotherapy through target discovery
Oxford, CA, UK
Oxford BioTherapeutics (OBT) is a clinical-stage oncology company based in Oxford, UK, and San Jose, USA. It is dedicated to discovering and developing first-in-class antibody-based therapies for cancer, with a pipeline including immuno-oncology and antibody-drug conjugate therapies.
How We Help
Problem Statement
Developing first-in-class antibody-based therapies to address unmet needs in cancer treatment.
Core Technology
Proprietary proteomic target discovery platform called OGAP®-Verify, based on one of the world's largest proprietary cancer membrane proteomic databases.
Key Differentiators
First-in-class antibody-based therapies for cancer; Proprietary proteomic target discovery platform (OGAP®-Verify)
Clinical Focus
Immuno-oncology; Antibody-drug conjugates
Company Info
- Business Model
- B2B
- Total Funding
- 14,600,000
- Website
- www.oxfordbiotherapeutics.com/
Categories
Disease Areas
Technologies
Clinical & IP
Clinical Validation
Phase 1b active for OBT076 (CD205 ADC); FDA IND cleared; initial Phase 1 data: 7/18 patients clinical benefit, optimal dose 3.0 mg/kg, well tolerated; Phase 2a planned for NSCLC, ovarian, gastric cancers; Phase 1b with checkpoint inhibitor combinations shows near-complete responses.
MedStartr Index Score
?What do you think of Oxford BioTherapeutics?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.